<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02445534</url>
  </required_header>
  <id_info>
    <org_study_id>RECORD</org_study_id>
    <nct_id>NCT02445534</nct_id>
  </id_info>
  <brief_title>Registry of Cell Therapy in Non-Ischemic Dilated Cardiomyopathy</brief_title>
  <acronym>RECORD</acronym>
  <official_title>Registry of Cell Therapy in Non-Ischemic Dilated Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although several studies have demonstrated beneficial effects of stem cell therapy in
      patients with non-ischemic dilated cardiomyopathy, the long term benefits and predictors of
      response to therapy remain undefined. The aim of this registry is to pool long-term clinical
      data in patients with non-ischemic dilated cardiomyopathy undergoing autologous cell therapy
      in an attempt to better define predictors of response to such treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Registry will include all patients who underwent intracoronary or intramyocardial cell
      therapy as a part of clinical trials performed at UMC Ljubljana from January 2005 until
      January 2018. Patients will be followed on regular basis in a dedicated heart failure
      outpatient clinic, clinical data will be collected and stored in a secure central database.
      Data will be analyzed in periodic intervals by an independent Data monitoring board in an
      attempt to better define the predictors of clinical response to cell therapy in this patient
      population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Transplantation-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Survival after 5 years without undergoing heart transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in left ventricular ejection fraction</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in left ventricular dimensions</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in left ventricular diastolic function</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in right ventricular function</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in exercise capacity</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in NT-proBNP</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Cardiomyopathy, Dilated</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous stem cell therapy</intervention_name>
    <description>All patients received granulocyte-colony stimulating factor (G-CSF; 5 mg/kg, 5 days). CD34+ cell were then collected by apheresis and injected transendocardially or intracororonary.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients enrolled in clinical trials of stem cell therapy in non-ischemic dilated
        cardiomyopathy at UMC Ljubljana from January, 2005 will be enrolled.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient inclusion criteria consisted of the following: age 18-65 years old, diagnosis
             of DCM according to the European Society of Cardiology position statement (9), optimal
             medical management for at least 6 months, left ventricular ejection fraction (LVEF)
             &lt;40%, and New York Heart Association functional Class III on stable medical therapy
             for at least 3 months before referral.

        Exclusion Criteria:

          -  Patients with acute multi-organ failure or a history of hematologic neoplasms were not
             included.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bojan Vrtovec, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Ljubljana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bojan Vrtovec, MD, PhD</last_name>
    <phone>+3861 522 1157</phone>
    <email>bojan.vrtovec@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gregor Poglajen, MD, PhD</last_name>
    <phone>+3861 522 1148</phone>
    <email>gregor.poglajen@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UMC Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bojan Vrtovec, MD, PhD</last_name>
      <phone>+3861 522 1157</phone>
      <email>bojan.vrtovec@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Gregor Poglajen, MD, PhD</last_name>
      <phone>+3861 522 1148</phone>
      <email>gregor.poglajen@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2015</study_first_submitted>
  <study_first_submitted_qc>May 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2015</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Bojan Vrtovec</investigator_full_name>
    <investigator_title>Medical Director, Advanced Heart Failure and Transplantation Center</investigator_title>
  </responsible_party>
  <keyword>Cell Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

